Wildon Farwell, MD, MPH, is Senior Medical Director in Clinical Development at Biogen. In his role, Dr. Farwell is the clinical development lead for SPINRAZA (nusinersen) at Biogen and has been part of the program since 2011. Dr. Farwell has extensive experience in rare disease clinical development. Prior to his work in spinal muscular atrophy (SMA), Dr. Farwell was also a Medical Director in the Safety and Benefit Risk function at Biogen where he participated in the Hemophilia and ALS programs. Prior to coming to Biogen in 2010, Dr. Farwell was Assistant Professor of Medicine at Harvard Medical School and on faculty at Brigham and Women’s Hospital and the VA Boston Healthcare System.
Dr. Farwell holds a medical degree from University of Missouri, Columbia and has a MPH in Clinical Effectiveness from Harvard School of Public Health.